The Psychic Tourniquet: Ultra-Low-Dose Buprenorphine for Acute Suicidality - PsyQ Episode 37

In this episode of PsyQ, we confront the "zone of danger" in acute suicidality—the critical lag period where standard antidepressants often fail to address immediate "psychache". Anchored by the seminal Yovell et al. (2016) randomized controlled trial, we explore the neurobiological overlap between physical and social pain , testing the hypothesis that ultra-low-dose buprenorphine (starting at 0.1 mg) can modulate the endogenous opioid system to treat separation distress directly. We dissect the study's groundbreaking findings—including a significant reduction in suicidal ideation distinct from depression improvement and robust efficacy in patients with Borderline Personality Disorder —while rigorously outlining the safety parameters, zero-withdrawal protocols, and the critical clinical distinction between treating specific depressive symptoms and soothing the primal agony of the PANIC/GRIEF system. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit upathak.substack.com